Stem cell therapies for cancers that resist immunotherapy
Raised to date
$3.3M
of $15M offered across 2 Form D filings
iOncologi, Inc. (iOi) is an innovative biotechnology company dedicated to pioneering novel immunotherapies for the treatment of refractory cancers and infectious diseases. With a strong emphasis on addressing the unmet medical needs of cancer patients who do not respond to existing treatments, iOncologi is at the forefront of transforming cancer therapy through advanced scientific research and development.
iOncologi stands out due to its exclusive rights to cutting-edge stem cell therapies and mRNA vaccine technologies, coupled with its comprehensive approach that integrates genomics and artificial intelligence in the fight against refractory cancers.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| May 23, 2025 | Security to be acquired | $250K/ $12M | Form D |
| Mar 5, 2025 | Security to be acquired | $3M/ $3M | Form D |
Immunotherapy
IONC201 and IONC202 are advanced immunomodulatory stem cell therapies specifically designed to circumvent resistance to PD-1 blockade. They work by enhancing anti-tumor immune responses, offering a promising solution for patients who exhibit resistance to traditional immunotherapy.
Built for
Cancer patients, particularly those with refractory cancers
